

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)



(10) International Publication Number
WO 2024/015981 A3

(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 27/02 (2006.01)
A61F 9/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2023/070241

(22) International Filing Date:

14 July 2023 (14.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/389,355 14 July 2022 (14.07.2022) US

(71) Applicant: **CHARACTER BIOSCIENCES, INC.**
[US/US]; 155 Second Street, Jersey City, New Jersey 07302
(US).

(72) Inventors: **KARRER, Erik**; 155 Second Street, Jersey
City, New Jersey 07302 (US). **AVRUTSKY, Maria**; 155
Second Street, Jersey City, New Jersey 07302 (US). **GU-**
MUCIO, Jonathan; 155 Second Street, Jersey City, New
Jersey 07302 (US). **VAN DER BRUG, Marcel**; 155 Second
Street, Jersey City, New Jersey 07302 (US).

(74) Agent: **SHOOP, Richard D.**; Shay Glenn LLP, 155 Bovet
Road, Suite 710, San Mateo, California 94402 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

14 March 2024 (14.03.2024)

(54) Title: THERAPEUTIC COMPOSITIONS AND METHODS FOR AGE-RELATED MACULAR DEGENERATION

CFH SCR1-7

FHL-1 SCR7
Junction

linker

CFH SCR6
Junction

FHL-1 SCR6-7

FIG. 2

(57) Abstract: An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

WO 2024/015981 A3